John Radcliffe 2 Hospital

Oxford, United Kingdom

John Radcliffe 2 Hospital

Oxford, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Blazek B.,Faculty Hospital Ostrava | Misbah S.A.,John Radcliffe 2 Hospital | Soler-Palacin P.,Hospital Universitari Vall dHebron | McCoy B.,Baxter BioScience | And 5 more authors.
Immunotherapy | Year: 2015

Aim: To document the therapeutic efficacy and safety of Human Normal Immunoglobulin 10% Liquid (KIOVIG®/GAMMAGARD LIQUID® [IVIG 10%]) under clinical routine conditions. Patients & methods: Subjects received IVIG 10% according to the prescribing information and were followed for 6 ± 1 weeks to 12 ± 2 months depending on indication. Efficacy, adverse events, infusion rates and duration and dose were recorded. Results: Overall efficacy of IVIG 10% was rated as good or very good by the investigator in 81.8% of subjects; overall tolerability was good or very good in 87.5%. One serious adverse drug reaction (ADR) occurred (urticaria); no severe ADRs occurred. Conclusion: In this observational study, the efficacy and safety of IVIG 10% in routine clinical practice was similar to that previously reported in clinical studies. © 2015 Future Medicine Ltd.

Loading John Radcliffe 2 Hospital collaborators
Loading John Radcliffe 2 Hospital collaborators